Tumor Rejection Antigens and Immune Surveillance

  • B. Van den Eynde
  • B. Lethé
  • A. Van Pel
  • T. Boon
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 35)

Abstract

The existence of specific tumor rejection antigens was first demonstrated with chemically induced mouse sarcomas: each tumor was found to express a different antigen [1]. Similar findings were made with ultraviolet-induced tumors [2]. Later, the generality of the existence of tumor rejection antigens was questioned when spontaneous mouse tumors were found to be completely incapable of eliciting an immune rejection response [3]. However, further experiments demonstrated that even these tumors express weak transplantation antigens that are potential targets for immune rejection by the syngeneic host [4].

Keywords

Leukemia Influenza Sarcoma Arginine Histidine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Prehn RT, Main JM (1957) Immunity to methylcholanthrene-induced sarcomas. INCI 18:769Google Scholar
  2. 2.
    Kripke MI (1981) Immunologic mechanism in UV radiation carcinogenesis. Adv Cancer Res 34:69PubMedCrossRefGoogle Scholar
  3. 3.
    Hewitt HB, Blake ER, Walder AS (1976) A critique of the evidence for active host defense against cancer based on personal studies of 27 murine tumors of spontaneous origin. Br J Cancer 33:241PubMedCrossRefGoogle Scholar
  4. 4.
    Van Pel A, Vessière F, Boon T (1983) Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis. J Exp Med 157:1992PubMedCrossRefGoogle Scholar
  5. 5.
    Boon T, Kellerman O (1977) Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant terato-carcinoma cell line. Proc Natl Acad Sci USA 74:272PubMedCrossRefGoogle Scholar
  6. 6.
    Frost P, Kerbel R, Bauer E, Tartamella-Biondo R, Cefalu W (1983) Mutagen treatments as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors. Cancer Res 43:125PubMedGoogle Scholar
  7. 7.
    Boon T, van Pel A (1978) Teratocar-cinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc Natl Acad Sci USA 75:1519PubMedCrossRefGoogle Scholar
  8. 8.
    Boon T, van Snick J, van Pel A, Uyttenhove C, Marchand M (1980) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. T lymphocyte-mediated cytolysis. J Exp Med 152:1184PubMedCrossRefGoogle Scholar
  9. 9.
    Maryanski JL, van Snick J, Cerottini JC, Boon T (1982) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur J Immunol 12:401PubMedCrossRefGoogle Scholar
  10. 10.
    Maryanski JL, Boon T (1982) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. Analysis of variants-specific antigens by selection of antigen-loss variants with cytolytic T-cell clones. Eur J Immunol 12:406PubMedCrossRefGoogle Scholar
  11. 11.
    Maryanski J, Marchand M, Uyttenhove C, Boon T (1983) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. Occasional escape from host rejection due to antigen-loss secondary variants. Int J Cancer 31:119PubMedCrossRefGoogle Scholar
  12. 12.
    Van Pel A, de Plaen E, Boon T (1985) Selection of highly transfectable variant from mouse mastocytoma P815. Somatic Cell Mol Genet 11:467CrossRefGoogle Scholar
  13. 13.
    Wölfel T, van Pel A, de Plaen E, Lurquin C, Maryanski JL, Boon T (1987) Immunoenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. Detection of stable transfectants expressing a tun - antigen with a cytolytic T cell stimulation assay. Immunogenetics 26:178PubMedCrossRefGoogle Scholar
  14. 14.
    De Plaen E, Lurquin C, van Pel A, Mariamé B, Szikora JP, Wölfel T, Sibille C, Chomez P, Boon T (1988) Immunogenic (tum) variants of mouse tumor P815: cloning of the gene of tun antigen P91A and identification of the tun mutation. Proc Natl Acad Sci USA 85:2274PubMedCrossRefGoogle Scholar
  15. 15.
    Szikora JP, van Pel A, Brichard V, André M, van Baren N, Henry P, de Plaen E, Boon T (1990) Structure of the gene of tun- transplantation antigen P35B: pre-sence of a point mutation in the antigenic allele. EMBO J 9:1041PubMedGoogle Scholar
  16. 16.
    Sibille C, Chomez P, Wildmann C, van Pel A, de Plaen E, Maryanski JL, de Bergeyck V, Boon T (1990) Structure of the gene of tun- transplantation antigen P198: a point mutation generates a new antigenic peptide. J Exp Med 172:35PubMedCrossRefGoogle Scholar
  17. 17.
    Lurquin C, van Pel A, Mariamé B, de Plaen E, Szikora JP, Janssens C, Reddehase MJ, Lejeune J, Boon T (1989) Structure of the gene of tun- transplantation antigen P91 A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 58:293PubMedCrossRefGoogle Scholar
  18. 18.
    Townsend ARM, Gotch FM, Davey J (1985) Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 42:457PubMedCrossRefGoogle Scholar
  19. 19.
    Townsend ARM, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ (1986) The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44:959PubMedCrossRefGoogle Scholar
  20. 20.
    Townsend ARM, Bastin J, Gould K, Brownlee GG (1986) Cytotoxic T lymphocytes recognize influenza haemagglu-tinin that lacks a signal sequence. Nature 324:575PubMedCrossRefGoogle Scholar
  21. 21.
    Van den Eynde B, Lethé ?, van Pel A, de Plaen E, Boon T (1991) The gene coding for the main tumor rejection antigen of mouse tumor P815 is identical to the normal gene of the syngeneic DBA/2 mice. J Exp Med 173:1373PubMedCrossRefGoogle Scholar
  22. 22.
    Uyttenhove C, Maryanski J, Boon T (1983) Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 157:1040PubMedCrossRefGoogle Scholar
  23. 23.
    Hültner L, Moeller J, Schmitt E, Jäger G, Reisbach G, Ring J, Dörmer P (1989) Thiol-sensitive mast cell lines derived from mouse bone marrow respond to a mast cell growth-enhancing activity different from both IL-3 and IL-4. J Immunol 142:3440PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • B. Van den Eynde
  • B. Lethé
  • A. Van Pel
  • T. Boon
    • 1
    • 2
  1. 1.Brussels BranchLudwig Institute for Cancer ResearchBrusselsBelgium
  2. 2.Cellular Genetics UnitUniversity of LouvainBrusselsBelgium

Personalised recommendations